Suraksha Diagnostic Limited — Investor Meet, 12-02-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Suraksha Diagnostic reported Q3 FY'26 revenue of INR 78.31 Cr (up 30.3% YoY) and 9M FY'26 revenue of INR 231.38 Cr (up 21.86%). Q3 EBITDA grew 26.1% to INR 23.78 Cr, with a 30.6% margin. Strong volume growth from new centers (12 operational, 6 in execution) is a priority, causing temporary margin compression (9M EBITDA margin 32.1%). Management expects margins to improve from Q3 FY'27 as centers mature, targeting 100 centers by FY'28. The genomics vertical 'Suraksha Sutra' positions Suraksha with the first complete genomic lab in Eastern India, driving future growth. The company has a net cash position of INR 29 Cr.